Literature DB >> 27922888

Experience with Extracorporeal Life Support for Cardiogenic Shock in the Older Population more than 70 Years of Age.

Margaux Pontailler1, Pierre Demondion, Guillaume Lebreton, Jean-Louis Golmard, Pascal Leprince.   

Abstract

The two main objectives of this single-center, retrospective study were to analyze the outcomes and to identify the independent predictors of 30 day and long-term mortality in case of cardiopulmonary resuscitation requiring extracorporeal life support (ECLS) in the elderly patients. From October 2004 to May 2014, 163 patients with a mean age of 75.5 years (range 70-91) required veno-arterial ECLS. The main indication was postcardiotomy cardiogenic shock (79.6%). Extracorporeal life support duration averaged 5.6 ± 4.3 days. Thirty-day mortality was 72% (n = 117) and follow-up survival rate was 14.1% with a median follow-up of 23.7 months (range 1.5-102.3). Lactatemia was identified as an independent risk factor of 30 day mortality. Previous stroke, lactatemia, bilirubinemia, and ECLS implantation under cardiac massage were identified as independent risk factors for long-term mortality. Extracorporeal life support after TAVI procedure and intra-aortic balloon pump support were identified as protective factors for both 30 day and long-term survival. The 23 patients, still alive at last follow up, have a good quality of life, doing well, and self-catering. Although mortality rate at 30 days is more than 70% in elderly patients requiring circulatory support with ECLS, survivors can pretend to an acceptable long-term survival with a good quality of life. Extracorporeal life support implantation in the elderly patients should remain scarce, but should still be considered as a therapeutic option in well-selected patients.

Entities:  

Mesh:

Year:  2017        PMID: 27922888     DOI: 10.1097/MAT.0000000000000484

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  6 in total

1.  The dilemma of patient age in decision-making for extracorporeal life support in cardiopulmonary resuscitation.

Authors:  Roberto Lorusso; Alain Cariou; Hans Flaatten
Journal:  Intensive Care Med       Date:  2018-12-07       Impact factor: 17.440

Review 2.  Percutaneous support of the failing left and right ventricle-recommendations for the use of mechanical device therapy.

Authors:  Sven Möbius-Winkler; Michael Fritzenwanger; Rüdiger Pfeifer; P Christian Schulze
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 3.  Management of Peripheral Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock.

Authors:  Steven P Keller
Journal:  Crit Care Med       Date:  2019-09       Impact factor: 7.598

4.  Venoarterial Extracorporeal Membrane Oxygenation for Postcardiotomy Shock-Analysis of the Extracorporeal Life Support Organization Registry.

Authors:  Mariusz Kowalewski; Kamil Zieliński; Daniel Brodie; Graeme MacLaren; Glenn Whitman; Giuseppe M Raffa; Udo Boeken; Kiran Shekar; Yih-Sharng Chen; Christian Bermudez; David D'Alessandro; Xiaotong Hou; Jonathan Haft; Jan Belohlavek; Inga Dziembowska; Piotr Suwalski; Peta Alexander; Ryan P Barbaro; Mario Gaudino; Michele Di Mauro; Jos Maessen; Roberto Lorusso
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 9.296

5.  Periprocedural Cardiopulmonary Bypass or Venoarterial Extracorporeal Membrane Oxygenation During Transcatheter Aortic Valve Replacement: A Systematic Review.

Authors:  Saraschandra Vallabhajosyula; Sri Harsha Patlolla; Harigopal Sandhyavenu; Saarwaani Vallabhajosyula; Gregory W Barsness; Shannon M Dunlay; Kevin L Greason; David R Holmes; Mackram F Eleid
Journal:  J Am Heart Assoc       Date:  2018-07-09       Impact factor: 5.501

6.  Shifting surgical archetypes of ICG fluorescent-angiography for bowel perfusion assessment in cardiogenic shock under ECMO support.

Authors:  Rene Aleman; Matthew Labkovski; Sinal Patel; Nikita Zadneulitca; Joel S Frieder; Raul J Rosenthal; Cedric Sheffield; Jose Navia; Nicolas A Brozzi
Journal:  J Card Surg       Date:  2022-04-21       Impact factor: 1.778

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.